Stephanie Astrow, PhD, MBA

Healthcare executive and scientist with 25+ years of leadership in biotechnology, focused on turning scientific innovation into commercial and clinical impact. Proven track record advancing first-in-class therapies and diagnostics, securing FDA clearances, and driving growth across public and private companies—including generating $10M+ in oncology revenue, expanding diagnostic portfolios, and managing a $30M P&L. Currently Chief Scientific Officer at Chimeric Therapeutics, contributing to corporate strategy and global cell therapy development while advising boards on risk, innovation, and long-term value creation.